Loading…
TARO-QUINAPRIL is a brand name for Quinapril, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: TARO-QUINAPRIL (Quinapril Tablets) is indicated for: • Hypertension: treatment of essential hypertension. It is usually administered in association with other drugs, particularly thiazide diuretics. • Congestive Heart Failure: treatment of congestive heart failure as adjunctive therapy when added to diuretics and/or…
Verbatim from this product's HC label. Tap a section to expand.
1 Dosing Considerations Dosage of TARO-QUINAPRIL must be individualized. 2 Recommended Dose and Dosage Adjustment Hypertension Initiation of therapy requires consideration of recent antihypertensive drug treatment, the extent of blood pressure (BP) elevation and salt restriction.
The dosage of other antihypertensive agents being used with TARO-QUINAPRIL may need to be adjusted.
PrTARO-QUINAPRIL (Quinapril Tablets) Page 6 of 46 Monotherapy:
The recommended initial dose of TARO-QUINAPRIL in patients not on diuretics is 10 mg once daily. An initial dose of 20 mg once daily can be considered for patients without advanced age, renal impairment, or concomitant heart failure and who are not volume depleted (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension).
Dosage should be adjusted according to BP response, generally at intervals of 2-4 weeks. A dose of 40 mg daily should not be exceeded. In some patients treated once daily, the antihypertensive effect may diminish towards the end of the dosing interval.
This can be evaluated by measuring BP just prior to dosing to determine whether satisfactory control is being maintained for 24 hours. If it is not, either 2x daily administration with the same total daily dose, or an increase in dose should be considered.
If BP is not controlled with TARO-QUINAPRIL alone, a diuretic may be added. After the addition of a diuretic, it may be possible to reduce the dose of TARO-QUINAPRIL.
Concomitant Diuretic Therapy:
Symptomatic hypotension occasionally may occur following the initial dose of TARO-QUINAPRIL and is more likely in patients who are currently being treated with a diuretic. The diuretic should, if possible, be discontinued for 2-3 days before beginning therapy with TARO-QUINAPRIL to reduce the likelihood of hypotension depleted (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension).
If the diuretic cannot be discontinued, an initial dose of 5 mg TARO-QUINAPRIL should be used with careful medical supervision for several hours and until BP has stabilized. The dosage of TARO-QUINAPRIL should subsequently be titrated (as described above) to the optimal response.
). 2 Breast- feeding). 73 m2), o hyperkalemia (> 5mMol/L) or o congestive heart failure who are hypotensive (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular, Dual blockade of the Renin-Angiotensin System (RAS)and Renal, Renal Impairment, and
, Immune, Head and Neck Angioedema). • Combination with sacubitril/valsartan due to increased risk of angioedema. TARO-QUINAPRIL must not be initiated until at least 36 hours have elapsed following discontinuation of sacubitril/valsartan therapy.
If treatment with TARO-QUINAPRIL is stopped, sacubitril/valsartan therapy must not be initiated until 36 hours after the last dose of TARO- QUINAPRIL. 1 Pregnant Women and
TARO-QUINAPRIL is contraindicated in: • Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
• Patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme (ACE) inhibitor (see 7 WARNINGS AND PRECAUTIONS, Immune, Head and Neck Angioedema). • Combination with sacubitril/valsartan due to increased risk of angioedema.
TARO-QUINAPRIL must not be initiated until at least 36 hours have elapsed following discontinuation of sacubitril/valsartan therapy. If treatment with TARO-QUINAPRIL is stopped, sacubitril/valsartan therapy must not be initiated until 36 hours after the last dose of TARO- QUINAPRIL.
1 Pregnant Women and 8 ADVERSE REACTIONS). 2 Breast- feeding). 4 Drug-Drug Interactions, Aliskiren- containing medicines and Angiotensin receptor blockers (ARBs)). 73m2), o hyperkalemia (> 5mMol/L) or o congestive heart failure who are hypotensive (see DRUG INTERACTIONS, Angiotensin receptor blockers (ARBs).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Quinapril in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Dosing Adjustment in Renal Impairment:
For use in hemodialysis patients, see 7 WARNINGS AND PRECAUTIONS, Immune, Anaphylactoid Reactions during Membrane Exposure. Quinapril should be administered on days when dialysis is not performed. 5 <10 Insufficient data for dosage recommendation Patients should subsequently have dosage titrated (as described above) to the optimal response.
Dosage in the Elderly (>65 years):
The recommended initial dosage of TARO-QUINAPRIL is 10 mg once daily (depending on renal function), followed by titration (as described above) to the optimal response. Congestive Heart Failure TARO-QUINAPRIL is indicated as adjunctive therapy to diuretics, and/or cardiac glycosides.
Therapy should be initiated under close medical supervision. BP and renal function should be monitored, both before and during treatment with TARO-QUINAPRIL, because severe hypotension PrTARO-QUINAPRIL (Quinapril Tablets) Page 7 of 46 and, more rarely, consequent renal failure have been reported (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension).
Initiation of therapy requires consideration of recent diuretic therapy and the possibility of severe salt/volume depletion. If possible, the dose of diuretic should be reduced before beginning treatment, to reduce the likelihood of hypotension.
Serum potassium should also be monitored (see 7 WARNINGS AND PRECAUTIONS and 9 DRUG INTERACTIONS). The recommended starting dose is 5 mg once daily, to be administered under close medical supervision to determine the initial effect on BP.
After the initial dose, the patient should be observed for ≥2 hours, or until the pressure has stabilized for ≥1 additional hour (See 7 WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension). This dose may improve symptoms of heart failure, but increases in exercise duration have generally required higher doses.
Therefore, if the initial dosage of TARO-QUINAPRIL is well tolerated or after effective management of symptomatic hypotension following initiation of therapy, the dose should then be increased gradually to 10 mg once daily, then 20 mg once daily, and to 40 mg per day given in 2 equally divided doses, depending on the patient's response.
The maximum daily dose is 40 mg. The dose titration may be done at weekly intervals, as indicated by the presence of residual signs or symptoms of heart failure.
Renal Impairment or Hyponatremia:
Kinetic data indicate that Quinapril Tablets elimination is dependent on the level of renal function. 5 mg in patients with a creatinine clearance of 10-30 mL/min. There is insufficient data for dosage recommendation in patients with a creatinine clearance <10 mL/min.
If the initial dose is well tolerated, TARO-QUINAPRIL may be administered the following day as a 2x daily regimen. In the absence of excessive hypotension or significant deterioration of renal function, the dose may be increased at weekly intervals based on clinical and hemodynamic response (See 7 WARNINGS AND PRECAUTIONS and 8 ADVERSE REACTIONS).
4 Missed Dose A patient missing a dose should take it as soon as they remember to. If it is almost time for the next dose, the missed dose should be skipped. The patient should be cautioned against taking two doses concomitantly to “make up” for the missed dose.